| Literature DB >> 34478878 |
Daniela Pugliese1, Giuseppe Privitera2, Tommaso Schepis2, Luigi Larosa3, Sara Onali4, Franco Scaldaferri1, Antonio Gasbarrini5, Flavio Caprioli6, Alessandro Armuzzi7.
Abstract
Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receiving anti-tumor necrosis factor α, rituximab, and tocilizumab.1,2 To date, only 4 reports of vedolizumab-related pneumonitis have been presented.3-5.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34478878 DOI： 10.1016/j.cgh.2021.08.041
Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN： 1542-3565 Impact factor: 11.382